12.16.2023 - By Dr. John Fralick and Dr. Michael Fralick
Welcome back Rounds Table Listeners! As we approach the end of 2023, let’s revisit five important research studies from 2022: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (0:00 – 2:56) Tirzepatide Once Weekly for the Treatment of Obesity (2:56 – 6:00) Empagliflozin in Patients with Chronic Kidney Disease (6:00 – ...
The post TBT – The Top Papers of 2022 appeared first on Healthy Debate.